Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.65 |
| ▸ | CA1 | P00915 | 4/20 | 0.65 |
| ▸ | CASP3 | P42574 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 2/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.51 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL697053 | 1.00 | CA2 (0.65) | CA2CA1CASP3GAAMAPT | |
| SCHEMBL712931 | 1.00 | CA2 (0.65) | CA2CA1CASP3GAAMAPT | |
| SCHEMBL29159682 | 0.98 | CA2 (0.63) | CA2CA1CASP3GAAMAPT | |
| SCHEMBL28334970 | 0.86 | CA2 (0.50) | CA2CA1ACEPTPN1SLC1A2 | |
| SCHEMBL9829896 | 0.86 | CA2 (0.66) | CA2CA1CASP3PTPN1TMPRSS15 | |
| SCHEMBL5280601 | 0.86 | CA2 (0.68) | CA2CA1ACEPTPN1SLC1A2 | |
| SCHEMBL9829891 | 0.86 | CA2 (0.66) | CA2CA1CASP3PTPN1TMPRSS15 | |
| SCHEMBL5191250 | 0.86 | CA2 (0.68) | CA2CA1ACEPTPN1SLC1A2 | |
| Phenylalanine SCHEMBL10413087 | 0.85 | SLC7A5 (0.59) | CA2CA1GAAMAPTACE | |
| SCHEMBL20875154 | 0.84 | CTSL (0.50) | CA2CA1CASP3GAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | DSM FINE CHEMICALS AUSTRIA NFG GMBH & CO KG (AT) | 2007-05-17 | — | — | US | claimed |
| EP-1457487-A1 | PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE CIS-PIPERIDINE DERIVATIVES | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-15 | — | — | EP | claimed |
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN, (JP) | 2004-09-02 | — | — | US | claimed |
| US-4213784-A | Process for producing heat developable light-sensitive compositions and elements | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-22 | — | — | US | claimed |
| CN-117083088-A | Folate receptor targeted radiotherapy agent and use thereof | 诺华股份有限公司 | 2023-11-17 | — | — | CN | disclosed |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | THE UNIVERSITY OF TOLEDO (US) | 2021-11-30 | — | — | US | disclosed |
| EP-3904446-A1 | NUCLEATING AGENT FOR POLYOLEFIN RESIN, NUCLEATING AGENT COMPOSITION FOR POLYOLEFIN RESIN CONTAINING SAME, MASTER BATCH FOR POLYOLEFIN RESIN, POLYOLEFIN RESIN COMPOSITION, MOLDED ARTICLE THEREOF, FILM THEREOF, METHOD FOR PRODUCING POROUS FILM, AND PACKAGE | ADEKA CORPORATION (JP) | 2021-11-03 | — | — | EP | disclosed |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2020-08-27 | — | — | US | disclosed |
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-13 | — | — | US | disclosed |
| WO-2017172476-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | THE UNIVERSITY OF TOLEDO (US) | 2017-10-05 | — | — | WO | disclosed |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-12-08 | — | — | US | disclosed |
| WO-2016116076-A1 | NEW POSSIBILITIES OF CHIRAL RESOLUTION OF BEDAQUILINE | ZENTIVA, K.S. (CZ) | 2016-07-28 | — | — | WO | disclosed |
| WO-1991002768-A1 | IMMOBILISATION OF LIGANDS BY RADIO-DERIVATIZED POLYMERS | EPIPHARM ALLERGIE-SERVICE GESELLSCHAFT M.B.H. (AT) | 1991-03-07 | — | — | WO | disclosed |
| EP-0132373-B1 | A NEUTRAL AMINO ACID COMPLEX AND A METHOD FOR OPTICAL RESOLUTION OF A DL-AMINO ACID | AJINOMOTO CO., INC. (JP) | 1988-10-05 | — | — | EP | disclosed |
| US-4661510-A | FUNGICIDES | SYNTEX (U.S.A.) INC. (US) | 1987-04-28 | — | — | US | disclosed |
| US-4610827-A | Amino acid complex and a method for optical resolution of a DL-amino acid | AJINOMOTO CO., INC. (JP) | 1986-09-09 | — | — | US | disclosed |
| EP-0134561-A1 | Alpha-allenic-alpha-amino acids | SYNTEX (U.S.A.) INC. (US) | 1985-03-20 | — | — | EP | disclosed |
| EP-0132373-A1 | A neutral amino acid complex and a method for optical resolution of a DL-amino acid | AJINOMOTO CO., INC. (JP) | 1985-01-30 | — | — | EP | disclosed |
| US-4213784-A | Process for producing heat developable light-sensitive compositions and elements | FUJI PHOTO FILM CO., LTD. (JP) | 1980-07-22 | — | — | US | disclosed |
| US-3948861-A | Polyamide-imides from bis-imide and dialdoxime | RHONE-POULENC S.A. (FR) | 1976-04-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171836-A1 | Method for producing optical-active cis-piperidine derivatives | TYR, DDC, TARBP1 | CA2 2307/4885CA1 2106/4885CASP3 1983/4885 |
| US-10123985-B2 | Therapeutic strategies for treating mitochondrial disorders | GOT2, GOT1, OTC | CA2 3025/4885CA1 3127/4885CASP3 2504/4885 |
| US-20200270202-A1 | POTENT INHIBITORS OF ASPARTATE N-ACETYL-TRANSFERASE FOR THE TREATMENT OF CANAVAN DISEASE | GOT1, ACAT1, GOT2 | CA2 1887/4885CA1 1312/4885CASP3 3754/4885 |
| US-11186541-B2 | Potent inhibitors of aspartate N-acetyl-transferase for the treatment of Canavan disease | GOT1, ACAT1, GOT2 | CA2 1887/4885CA1 1312/4885CASP3 3754/4885 |
| US-20160354332-A1 | THERAPEUTIC STRATEGIES FOR TREATING MITOCHONDRIAL DISORDERS | GOT2, GOT1, OTC | CA2 3025/4885CA1 3127/4885CASP3 2504/4885 |
| US-20070112216-A1 | Method for producing chiral mercapto amino acids | CPN1, AKR1C3, AHCY | CA2 361/4885CA1 113/4885CASP3 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.